Global Dual Specificity Protein Kinase Ttk Inhibitor Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global dual specificity protein kinase Ttk inhibitor market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global dual specificity protein kinase Ttk inhibitor market is expected to witness significant growth in the near future, driven by the growing number of protein kinase Ttk inhibitors approvals by U.S. FDA. For instance, in December 2021, NTRC, a Dutch-based precision medicine company specializing in the discovery and development of innovative kinase inhibitors to treat cancer patients, announced that the U.S. Food and Drug Administration (FDA) had approved an Investigational New Drug (IND) application for the novel kinase inhibitor BAL0891, a mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division, leading to tumor cell death. BAL0891 was developed by NTRC and licensed to Basilea Pharmaceutica International Ltd., a commercial stage biopharmaceutical company which is headquartered in Switzerland.
Dual Specificity Protein Kinase TTK Inhibitor Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients